Itepekimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Itepekimab
- IMMUNOGLOBULIN IGG4 (230-PROLINE), ANTI-(HUMAN INTERLEUKIN 33) (HUMAN MONOCLONAL REGN3500 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN3500 .KAPPA.-CHAIN, DIMER
- immunoglobulin igg4 230 proline anti human interleukin 33 human monoclonal regn3500 gamma 4 chain disulfide with human monoclonal regn3500 kappa chain dimer
- itepekimab
- Itepekimab
- Itepekimab (SAR440340)
- itepekimab [INN]
- ITEPEKIMAB [USAN]
- Itepekimab [WHO-DD]
- itepekimab inn
- itepekimab sar440340
- Itepekimab SAR440340
- itepekimab usan
- itepekimab who dd
- regn 3500
- REGN-3500
- regn3500
- Regn3500
- REGN3500
- sar 440340
- SAR-440340
- sar440340
- Sar440340
- SAR440340
- CAS registry numbers
- 2226742-52-3
- ChEMBL ID
- CHEMBL4594594
- FDA ingredient codes (UNII)
- WV9KZ9PS1A
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mab
Mechanisms of action
- Mechanism
- Interleukin-33 inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-33
- Protein identifier
- O95760
Open Targets mechanisms
- Mechanism
- Interleukin-33 inhibitor
- Action type
- Inhibitor
- Target
- Interleukin-33
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Asthma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_1002029
- Highest recorded phase
- 3
- Condition identifier
- EFO_1002030
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004784
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004822
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 3
- Condition identifier
- MP_0001845
- Highest recorded phase
- 1
- NCT02999711
- NCT03387852
- NCT03546907
- NCT04701983
- NCT04751487
- NCT05326412
- NCT06114238
- NCT06208306
- NCT03736967
- NCT03738423
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- 299 $ 299''''
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLVESGGNLEQPGGSLRLSCTASGFTFSRSAMNWVRRAPGKGLEWVSGISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLSAEDTAAYYCAKDSYTTSWYGGMDVWGHGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSVSASVGDRVTITCRASQGIFSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQANSVPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 136-214' $ 136'-214''' $ 149-205 $149''-205'' $ 228-228'' $ 231-231'' $ 263-323 $ 263''-323'' $ 369-427 $ 369''-427''
- Component
- Glycosylation sites (N)
- Sequence
- 299 $ 299''
Related records
Trials (18)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
- A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects
- A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
- An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
- Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
- Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
- Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe
- Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
- Study of REGN3500 and Dupilumab in Patients With Asthma
- Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
In development for (4)
- Asthma Phase 2
- Atopic eczema Phase 2
- Bronchiectasis Phase 2
- Chronic obstructive pulmonary disease Phase 3
Targets (1)
- IL33 Interleukin-33 inhibitor